TBUFF: Tribute Pharmaceuticals Canada Inc. (“Tribute”) will complete a plan of arrangement (the “Arrangement”) with Aralez Pharmaceuticals Inc. (“Aralez”) and ARLZ CA Acquisition Corp., resulting in Tribute becoming a wholly-owned subsidiary of Aralez. Pursuant to the Agreement, Pozen Inc. will merge with a wholly-owned subsidiary of Aralez and will become a wholly-owned subisidiary of Aralez. Shareholders of the Company shall receive 0.1455 shares of Aralez for each share of the Company.

FINRA deleted symbol:

http://otce.finra.org/DLDeletions

POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc. (2/05/16)

-Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio-

-Canadian Domicile Provides Compelling Platform for Growth with Competitive Structure-

-US$350 Million Capital Commitment from Deerfield-Led Syndicate-

MILTON, Ontario, Feb. 5, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion of the business combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction by stockholders of POZEN and shareholders of Tribute. The combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), a global specialty pharmaceutical company with operations in Canada, Ireland and the United States. Under the terms of the Agreement and Plan of Merger and Arrangement, each share of POZEN common stock has been converted into the right to receive one Aralez common share and each common share of Tribute (other than dissenting shares) has been exchanged for 0.1455 Aralez common shares.

As of closing, Aralez has approximately 75 million outstanding shares on a fully diluted basis. Commencing on or about February 8, 2016, Aralez will trade on NASDAQ under the ticker symbol "ARLZ", and on or about February 10, 2016 will begin trading on the Toronto Stock Exchange ("TSX") under the ticker symbol "ARZ".

"As Aralez, we have established an efficient platform that offers competitive advantages with committed capital to enable us to aggressively build out our portfolio through strategic business development and M&A, from which we plan to drive long-term value creation for shareholders," said Adrian Adams, Chief Executive Officer of Aralez. "We have a lean, nimble and performance-oriented operating business model that will allow us to build value organically and through accretive transactions and as such we believe that Aralez is well positioned for further transformational growth."

About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while focusing on creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the US Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.

http://www.prnewswire.com/news-releases/pozen-and-tribute-combine-to-create-aralez-pharmaceuticals-inc-300216066.html

POZEN Inc. Announces Stockholder Approval of its Transaction with Tribute Pharmaceuticals Canada Inc. (2/02/16)

-Transaction Expected to Close on or About February 5, 2016-

CHAPEL HILL, N.C., Feb. 2, 2016 /PRNewswire/ -- POZEN Inc. ("POZEN") (NASDAQ: POZN), a specialty pharmaceutical company, today announced that its stockholders approved the Agreement and Plan of Merger and Arrangement (the "Merger Agreement") with Tribute Pharmaceuticals Canada Inc. ("Tribute") and the carrying out of the transactions contained therein. Upon closing of the transaction, the POZEN and Tribute businesses will operate as subsidiaries of Aralez Pharmaceuticals Inc. ("Aralez"), a company domiciled in Canada.

The Merger Agreement was also adopted by the Tribute shareholders on February 1, 2016. The proposed transaction remains subject to certain conditions and approvals, including approval of the Ontario Superior Court of Justice, listing of Aralez shares and customary closing conditions, and is expected to occur promptly following satisfaction of all conditions. Aralez will be listed on the NASDAQ stock exchange under the ticker symbol "ARLZ" and is expected to begin trading on or about February 8, 2016, and will be listed on the Toronto Stock Exchange ("TSX") under the ticker symbol "ARZ" and is expected to begin trading on on or about February 10, 2016, assuming closing on February 5, 2016.

About POZEN
POZEN is a specialty pharmaceutical company that has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing this business model, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin to be realized by reducing its GI damage.

On June 2, 2015, POZEN announced the formation of Aralez Pharmaceuticals Trading DAC (formerly Pozen Limited), a wholly-owned Irish subsidiary, to expand its geographic footprint and increase its global presence, including potential international sales, manufacturing and product development.

POZEN's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

About Tribute
Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution 2%), Fiorinal®, Fiorinal® C, Visken®, Viskazide®, Collatamp® G, Durela®, Proferrin®, Iberogast®, MoviPrep®, Normacol®, Resultz®, Pegalax®, Balanse®, Balanse® Kids, Diaflor™, Mutaflor®, and Purfem® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the U.S. rights to Fibricor® and its related authorized generic. In addition, it has the exclusive U.S. rights to develop and commercialize Bezalip® SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. This product is subject to receiving Canadian regulatory approval.

Tribute's common shares are traded on the TSX Venture Exchange under the symbol "TRX" and on the OTCQX International under the symbol "TBUFF". For more detailed company information, including copies of this and other press releases, please visit www.tributepharma.com.

http://www.prnewswire.com/news-releases/pozen-inc-announces-stockholder-approval-of-its-transaction-with-tribute-pharmaceuticals-canada-inc-300213628.html

Tribute Announces Results of Shareholder Vote (2/01/16)

MILTON, ONTARIO--(Marketwired - Feb. 1, 2016) - Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it has received overwhelming shareholder approval of the previously announced plan of arrangement (the "Arrangement") with, among others, Aralez Pharmaceuticals Inc. ("Aralez") (see press release dated December 7, 2015), which forms part of the pending transaction with POZEN Inc. ("POZEN") (NASDAQ:POZN).

Of the votes cast at the Tribute shareholder's meeting held today, approximately 99.81% voted in favour of the special resolution approving the Arrangement.

The Company will now apply to the Ontario Superior Court of Justice (Commercial List) for a final order (the "Final Order") approving the Arrangement. The hearing in respect of the Final Order is expected to take place on February 2, 2016 at 10:00 a.m. (Toronto time) at 330 University Avenue, Toronto, Ontario.

Provided that the Final Order is granted, and the remaining conditions are satisfied including approval of the POZEN shareholders at its meeting scheduled for February 2, 2016, it is anticipated that the Arrangement will close on or about February 5, 2016.

Transaction Terms and Structure

In connection with the transaction, POZEN formed Aralez, organized under the laws of British Columbia, Canada. Pursuant to the terms of the proposed transaction, a Canadian subsidiary of Aralez ("Can Merger Sub") will amalgamate with Tribute by way of the Arrangement, Upon completion of the Arrangement, Tribute and Can Merger Sub will continue as one corporation ("Amalco") and Amalco will become a wholly-owned subsidiary of Aralez. Similarly, an indirect U.S. subsidiary of Aralez will merge with POZEN, with POZEN surviving as an indirect wholly-owned subsidiary of Aralez. At closing, each share of POZEN common stock will be converted into the right to receive one Aralez common share and each common share of Tribute (other than dissenting shares) will be exchanged for 0.1455 of an Aralez common share. As a result of the proposed transaction and before giving effect to a contemplated concurrent financing, stockholders of POZEN will own approximately 64 percent of Aralez and shareholders of Tribute will own approximately 36 percent of Aralez, in each case prior to giving effect to any exercise of any outstanding options or warrants or vesting and delivery of any restricted stock units of either company after the date hereof. It is a condition of closing that the common shares of Aralez be approved for listing on the NASDAQ, subject to official notice of issuance, and conditionally approved on the Toronto Stock Exchange ("TSX").

Additional Information and Where to Find It

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ ARALEZ'S REGISTRATION STATEMENT ON FORM S-4 AND POZEN'S RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS AS WELL AS TRIBUTE'S INFORMATION CIRCULAR BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT ARALEZ, POZEN, TRIBUTE AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents and other related documents filed with the SEC at the SEC's website at www.sec.gov. Investors and security holders may obtain free copies of the Information Circular and other documents filed by Tribute on the System for Electronic Document Analysis Retrieval ("SEDAR") website maintained by the Canadian Securities Administrators at www.sedar.com. Investors and security holders may obtain free copies of the documents filed by POZEN with the SEC on POZEN's website at www.pozen.com under the heading "Investors" and then under the heading "SEC Filings" and free copies of the documents filed by Tribute with the SEC on Tribute's website at www.tributepharma.com under the heading "Investors" and then under the heading "SEC Filings."

POZEN, Tribute and Aralez and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of POZEN and shareholders of Tribute and Aralez in connection with the proposed transaction. Information regarding the special interests, if any, of these directors and executive officers in the proposed transaction is included in the proxy statement/prospectus and Information Circular described above. Additional information regarding the directors and executive officers of POZEN and Tribute is contained in their respective annual reports on Form 10-K for the year ended December 31, 2014 filed with the SEC.

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

For full prescribing information refer to the individual product websites.

About Tribute

Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution 2%), Fiorinal®, Fiorinal® C, Visken®, Viskazide®, Collatamp® G, Durela®, Proferrin®, Iberogast®, MoviPrep®, Normacol®, Resultz®, Pegalax®, Balanse®, Balanse® Kids, Diaflor™, Mutaflor®, and Purfem® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to Fibricor® and its related authorized generic. In addition, it has the exclusive U.S. rights to develop and commercialize Bezalip® SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. This product is subject to receiving Canadian regulatory approval. Tribute also has the Canadian rights to ibSium®, which was approved in Canada in June 2015 and two additional pipeline products including Octasa® and BedBugz™, both of which are pending submission to Health Canada.

Tribute's common shares are traded on the TSX Venture Exchange under the symbol "TRX" and on the OTCQX International under the symbol "TBUFF". For more detailed company information, including copies of this and other press releases, please visit www.tributepharma.com.

About POZEN

POZEN is a specialty pharmaceutical company that has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing this business model, POZEN has successfully developed and obtained United States Food and Drug Administration ("FDA") approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin to be realized by reducing its GI damage.

POZEN's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

http://www.marketwired.com/press-release/tribute-announces-results-of-shareholder-vote-otcqx-tbuff-2092828.htm

Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction (1/21/16)

MILTON, ONTARIO--(Marketwired - Jan. 21, 2016) - Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that Institutional Shareholder Services ("ISS") and Glass Lewis & Co. ("Glass Lewis") have both recommended that Tribute shareholders vote FOR the special resolution (the "Arrangement Resolution") to approve the previously announced transaction (the "Transaction") with Pozen Inc. ("Pozen") and combination under Aralez Pharmaceuticals Inc. ("Parent"), to be considered at the upcoming special meeting of Tribute shareholders to be held on February 1, 2016 at 10:00 a.m. (Toronto time) at the offices of Fogler, Rubinoff LLP, located at 77 King Street West, Suite 3000, Toronto, Ontario.

In connection with the Transaction, each Tribute Shareholder will receive 0.1455 of a common share of Parent per Tribute common share ("Tribute Shares").

Both ISS and Glass Lewis are independent proxy advisory firms which, among other services, provide proxy voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.

The Board of Directors of Tribute unanimously recommends that Tribute shareholders vote FOR the Arrangement Resolution.

Shareholders are reminded to vote FOR the Arrangement Resolution prior to the voting deadline on January 28, 2016 at 10 a.m. EST (Toronto time).

Shareholders should now have received, and are urged to carefully review, the Management Information Circular (the "Circular") and accompanying proxy voting materials as they contain important information regarding the Transaction and its benefits to shareholders. Assuming a successful shareholder vote and satisfaction of the other conditions required for completion of the Transaction, closing is expected to occur in early February 2016.

How to Vote

Vote Today. Your vote is important regardless of the number of Tribute Shares you own.

Registered Shareholders

Tribute shareholders who own Tribute Shares directly and which are represented by a physical certificate, may vote via the internet at www.voteproxyonline.com or following the instructions found on their form of proxy.

Non-Registered Shareholders

Tribute shareholders who hold their Tribute Shares through a broker or other intermediary may vote via the internet at www.proxyvote.com or following the other instructions found on their voting instruction form.

The deadline to vote is January 28, 2016 at 10 a.m. EST (Toronto time). However, Tribute Shareholders are encouraged to vote well in advance of the deadline.

Shareholder Questions

Tribute shareholders who have questions or require assistance with voting may contact Laurel Hill Advisory Group, Tribute's proxy solicitation agent, toll-free at 1-877-452-7184 (416-304-0211 collect) or by email at assistance@laurelhill.com.

About Tribute

Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution), Uracyst® (sodium chondroitin sulfate solution 2%), Fiorinal®, Fiorinal® C, Visken®, Viskazide®, Collatamp® G, Durela®, Proferrin®, Iberogast®, MoviPrep®, Normacol®, Resultz®, Pegalax®, Balanse®, Balanse® Kids, Diaflor™, Mutaflor®, and Purfem® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to Fibricor® and its related authorized generic. In addition, it has the exclusive U.S. rights to develop and commercialize Bezalip SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. Bilastine is subject to receiving Canadian regulatory approval. Tribute also has the Canadian rights to ibSium®, which was approved in Canada in June 2015 and two additional pipeline products including Octasa® and BedBugz™, both of which are pending submission to Health Canada.

The Tribute Shares are traded on the TSX Venture Exchange under the symbol "TRX" and quoted on the OTCQX under the symbol "TBUFF". For more detailed company information, including copies of this and other press releases, please visit www.tributepharma.com.

About POZEN

POZEN Inc. is a specialty pharmaceutical company that has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

http://www.marketwired.com/press-release/leading-independent-advisors-recommend-that-tribute-shareholders-vote-for-transaction-otcqx-tbuff-2089994.htm

Tribute Mails Materials in Connection With Special Meeting of Shareholders to Approve Transaction With POZEN and Encourages Shareholders to Vote (1/11/16)

MILTON, ONTARIO--(Marketwired - Jan. 11, 2016) - Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., announced that the Management Information Circular dated January 5, 2016 (the "Circular") and accompanying materials for Tribute's special meeting to be held on February 1, 2016 (the "Meeting") relating to the previously announced proposed transaction (the "Transaction") with POZEN Inc. ("POZEN") and combination under Aralez Pharmaceuticals Inc. ("Parent"), have been mailed to Tribute shareholders ("Tribute Shareholders"). These materials are available online at Tribute's website at www.tributepharma.com or on SEDAR at www.sedar.com and on the United States Securities and Exchange Commission (the "SEC") website at www.sec.gov.

The Special Meeting

The Meeting will be held on February 1, 2016 at 10:00 a.m. EST at the offices of Fogler, Rubinoff LLP, Tribute's Canadian legal counsel, at 77 King Street West, Suite 3000, Toronto, Ontario.

At the Meeting, Tribute Shareholders will be asked to approve a special resolution (the "Arrangement Resolution") approving the Transaction with POZEN as described in the Circular.

Tribute Shareholders are urged to carefully review the Circular and accompanying materials, as they contain important information regarding the Transaction and its consequences to Tribute Shareholders. Tribute Shareholders of record as of the close of business on December 31, 2015 are entitled to vote at the Meeting.

The Consideration

Each Tribute Shareholder will receive 0.1455 of a common share of Parent ("Parent Shares") per Tribute common share.

Benefits of the Transaction and Board Recommendations

The Tribute Board of Directors believes that the Transaction will provide Tribute and the Tribute Shareholders with a number of significant strategic and financial benefits, including but not limited to the following:

•the benefits of the size and scale of Parent after giving effect to the combination of POZEN and Tribute and the expected pro forma effect of the proposed Transaction;

•the combined company will be a more diversified provider of specialty healthcare products with a focus on cardiovascular and pain indications;

•the Parent Shares offer Tribute Shareholders the opportunity to participate in the future earnings and growth of Parent, which will include the POZEN and Tribute revenue streams and the potential commercialization of POZEN's and Tribute's product candidates of the combined Parent entity;

•the Transaction would result in synergies, and Tribute Shareholders would participate in the benefits of these expected synergies;

•with the current and expected future landscape of the pharmaceutical industry, and, in light of the regulatory, financial and competitive challenges facing industry participants, the likelihood that Parent, pro forma for the combination of POZEN and Tribute, would be better positioned to meet these challenges if the expected strategic and financial benefits of the Transaction were fully realized;

•as a larger company, Parent will have greater ability to raise capital with rates and terms more advantageous to Parent and its shareholders; and

•having a tax efficient domicile will allow Parent to be more competitive and facilitate its goal to grow the combined business through product acquisition and merger and acquisition transactions.

The Board of Directors of Tribute unanimously recommends that Tribute Shareholders vote in favour of the Arrangement Resolution.

How to Vote

Vote Today. Your vote is important regardless of the number of Tribute Shares you own.

Registered Shareholders

Tribute Shareholders who own Tribute Shares directly and which are represented by a physical certificate, may vote via the internet at www.voteproxyonline.com or following the instructions found on their form of proxy.

Non-Registered Shareholders

Tribute Shareholders who hold their Tribute Shares through a broker or other intermediary may vote via the internet at www.proxyvote.com or following the other instructions found on their voting instruction form.

The deadline to vote is January 28, 2016 at 10 a.m. EST (Toronto time). However, Tribute Shareholders are encouraged to vote well in advance of the deadline.

Shareholder Questions

Tribute Shareholders who have questions or require assistance with voting may contact Laurel Hill Advisory Group, Tribute's proxy solicitation agent, toll-free at 1-877-452-7184 (416-304-0211 collect) or by email at assistance@laurelhill.com.

About Tribute

Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution), Uracyst® (sodium chondroitin sulfate solution 2%), Fiorinal®, Fiorinal® C, Visken®, Viskazide®, Collatamp® G, Durela®, Proferrin®, Iberogast®, MoviPrep®, Normacol®, Resultz®, Pegalax®, Balanse®, Balanse® Kids, Diaflor™, Mutaflor®, and Purfem® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to Fibricor® and its related authorized generic. In addition, it has the exclusive U.S. rights to develop and commercialize Bezalip SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. Bilastine is subject to receiving Canadian regulatory approval. Tribute also has the Canadian rights to ibSium®, which was approved in Canada in June 2015 and two additional pipeline products including Octasa® and BedBugz™, both of which are pending submission to Health Canada.

The Tribute Shares are traded on the TSXV under the symbol "TRX" and quoted on the OTCQX under the symbol "TBUFF". For more detailed company information, including copies of this and other press releases, please visit www.tributepharma.com.

About POZEN

POZEN Inc. is a specialty pharmaceutical company that has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

Additional Information and Where to Find It

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ TRIBUTE'S CIRCULAR AS IT CONTAINS IMPORTANT INFORMATION ABOUT PARENT, POZEN, TRIBUTE AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents and other related documents filed with the United States Securities and Exchange Commission ("SEC") at the SEC's website at www.sec.gov and on the System for Electronic Document Analysis Retrieval ("SEDAR") website maintained by the Canadian Securities Administrators at www.sedar.com or on Tribute's website at www.tributepharma.com under the heading "Investors" and then under the heading "SEC Filings".

Tribute and its respective directors and executive officers may be deemed participants in the solicitation of proxies from the Tribute Shareholders in connection with the Transaction. Information regarding the special interests, if any, of these directors and executive officers in the Transaction are included in the Circular described above. Additional information regarding the directors and executive officers of Tribute is contained in its Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC.

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains certain forward-looking statements about Tribute as defined in the applicable securities laws, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Such statements include, but are not limited to, statements related to the anticipated consummation of the Transaction and the timing and benefits thereof. Forward-looking statements, by their nature, are subject to risks and uncertainties. Tribute's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, any of which could cause actual results to vary materially from current results or anticipated future results, including but not limited to, those risks and uncertainties disclosed under the heading "Risk Factors" of the Company's annual report on Form 10-K for the fiscal year ended December 31, 2014 and its other filings filed with the United States Securities and Exchange Commission and Canadian securities regulatory authorities, which are available online at www.sec.gov and at www.sedar.com, respectively. Accordingly, readers should not place undue reliance on forward-looking statements. Tribute assumes no obligation to update any forward-looking statements.

Bezalip® SR and Soriatane® are registered trademarks and under license from Actavis Group PTC ehf. Cambia® is a registered trademark and under license from Depomed, Inc. Collatamp® G is a registered trademark and under license EUSA Pharma (Europe) Limited. Visken® and Viskazide® are registered trademarks under license with Novartis AG. Durela® is a registered trademark and under license from Cipher Pharmaceuticals Inc. Proferrin® is a registered trademark and under license from Colorado Biolabs, Inc. MoviPrep® and Normacol® are registered trademarks and under license from the Norgine group of companies. Iberogast® is a registered trademark and under license from Bayer Consumer Care AG.

For further information on Tribute, visit the Company's website: http://www.tributepharma.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

http://www.marketwired.com/press-release/tribute-mails-materials-connection-with-special-meeting-shareholders-approve-transaction-otcqx-tbuff-2086756.htm

Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia® Use in Migraine Treatment (1/04/16)

MILTON, ONTARIO--(Marketwired - Jan. 4, 2016) - Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,632,375, entitled "Diclofenac Formulations and Method of Use." This patent, which was developed by APR Applied Pharma Research s.a. (?APR?), a private, international corporation headquartered in Switzerland and focused on the development and commercialization of innovative healthcare products, is licensed exclusively to Tribute in Canada through a sub-license agreement with Depomed, Inc. (?Depomed?). Depomed has the exclusive North American rights to Cambia® licensed with APR. The issuance of the new patent will expand Tribute's intellectual property protection for Cambia®, currently indicated in Canada for the treatment of acute migraine in adults over 18 years of age.

"This important Canadian patent allowance extends our core intellectual property protection in a market that has been strategically significant to us since the initial launch of Cambia® in Canada in October 2012," stated Rob Harris, Tribute's President and Chief Executive Officer. "This new patent extends our intellectual property rights to June 6, 2026." IMS Health, an audited third party provider of sales data, reported an 89.2% increase in total prescriptions written for Cambia® during the three months ended September 30, 2015 compared to the three months ended September 30, 2014.

About Tribute

Tribute is a pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets. Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution), Uracyst® (sodium chondroitin sulfate solution 2%), Fiorinal®, Fiorinal® C, Visken®, Viskazide®, Collatamp® G, Durela®, Proferrin®, Iberogast®, MoviPrep®, Normacol®, Resultz®, Pegalax®, Balanse®, Balanse® Kids, Diaflor™, Mutaflor®, and Purfem® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to Fibricor® and its related authorized generic. In addition, it has the exclusive U.S. rights to develop and commercialize Bezalip® SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. Bilastine is subject to receiving Canadian regulatory approval. Tribute also has the Canadian rights to ibSium®, which was approved in Canada in June 2015 and two additional pipeline products including Octasa® and BedBugz™, both of which are pending submission to Health Canada. Tribute's common shares are traded on the TSX Venture Exchange under the symbol "TRX" and on the OTCQX International under the symbol "TBUFF". For more detailed company information, including copies of this and other press releases, please visit www.tributepharma.com.

About APR Applied Pharmaceutical Research

APR is a Swiss, independent developer of science-driven, patent-protected healthcare products. APR identifies, develops and licenses science-driven, value-added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. Specifically, APR is currently focused on two major areas: (i) internally developed and financed (alone or with our co-development partners) proprietary, value-added products to be licensed to healthcare companies for their commercialization, and (ii) support to third-party projects, by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products commercialized in all major markets, combined with a compelling pipeline of products at different development stages. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.

Tribute Pharmaceuticals' Forward-Looking Statements

This press release contains certain forward-looking statements about Tribute as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Such statements include, but are not limited to, the expansion of Tribute's intellectual property protection for Cambia® and the potential for Cambia in the Canadian market. Forward-looking statements, by their nature, are subject to risks and uncertainties. Tribute's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, any of which could cause actual results to vary materially from current results or anticipated future results, including but not limited to, those risks and uncertainties disclosed under the heading "Risk Factors" of the Company's annual report on Form 10-K for the fiscal year ended December 31, 2014 and its other filings filed with the United States Securities and Exchange Commission and Canadian securities regulatory authorities which are available online at www.sec.gov and at www.sedar.com, respectively. Accordingly, readers should not place undue reliance on forward-looking statements Tribute assumes no obligation to update any forward-looking statements.

Cambia® is a registered trademark and under license from Depomed.

For further information on Tribute visit the Company's website: www.tributepharma.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

http://www.marketwired.com/press-release/tribute-pharmaceuticals-receives-notice-allowance-canadian-patent-expanding-cambiar-tsx-venture-trx-2085187.htm

Tribute Schedules Special Shareholder Meeting for February 1, 2016 (12/28/15)

MILTON, ONTARIO--(Marketwired - Dec. 28, 2015) - Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its special meeting of shareholders in connection with the pending transaction with POZEN Inc. ("POZEN") (NASDAQ:POZN) will be held on February 1, 2016 at 10:00 a.m. EST, at the offices of Fogler, Rubinoff LLP at Suite 3000, 77 King Street West, Toronto, Ontario. This meeting is being held to seek shareholder approval of the proposed transaction and related matters. Tribute is expected to mail the meeting materials in early January. Tribute's shareholders of record as of the close of business on December 31, 2015 are entitled to vote at the meeting.

The Board of Directors of Tribute has unanimously recommended that Tribute shareholders vote to approve the transaction to be considered at Tribute's special meeting of its shareholders.

Transaction Terms and Structure

POZEN has formed a new company, Aralez Pharmaceuticals Inc. ("Aralez"), organized under the laws of British Columbia, Canada. Pursuant to the terms of the proposed transaction, a Canadian subsidiary of Aralez will amalgamate with Tribute, through a three-cornered amalgamation by way of a plan of arrangement, with Tribute surviving as a wholly-owned subsidiary of Aralez. Similarly, an indirect U.S. subsidiary of Aralez will merge with POZEN, with POZEN surviving as an indirect wholly-owned subsidiary of Aralez. At closing, each share of POZEN common stock will be converted into the right to receive one Aralez common share and each common share of Tribute (other than dissenting shares) will be exchanged for 0.1455 of an Aralez common share. This exchange ratio remains unchanged from the ratio announced when the parties initially entered into the agreement and plan of merger. As a result of the proposed transaction and before giving effect to the contemplated financing, stockholders of POZEN will own approximately 64 percent of Aralez and shareholders of Tribute will own approximately 36 percent of Aralez, in each case prior to giving effect to any exercise of any outstanding options or warrants or vesting and delivery of any restricted stock units of either company after the date hereof. As of December 7, 2015, POZEN had approximately 33.2 million common shares outstanding and 39.3 million fully diluted shares and Tribute had approximately 126.2 million common shares outstanding and 163.4 million fully diluted shares. It is a condition of closing that the common shares of Aralez be approved for listing on the NASDAQ, subject to official notice of issuance, and conditionally approved on the Toronto Stock Exchange ("TSX").

Additional Information and Where to Find It

In connection with the proposed transaction, Aralez, POZEN and Tribute have filed and will be filing additional documents with the United States Securities and Exchange Commission ("SEC"), including a Registration Statement on Form S-4 filed by Aralez on December 14, 2015 that includes the proxy statement/prospectus relating to the proposed transaction. The Registration Statement has been declared effective by the SEC. A definitive proxy statement/prospectus will be mailed to POZEN stockholders in connection with the proposed transaction. Upon receipt of an interim court order in respect of the plan of arrangement, Tribute will be mailing an Information Circular to its shareholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS AS WELL AS THE INFORMATION CIRCULAR WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ARALEZ, POZEN, TRIBUTE AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's website at www.sec.gov. Investors and security holders will be able to obtain free copies of the Information Circular and other documents filed by Tribute on the System for Electronic Document Analysis Retrieval ("SEDAR") website maintained by the Canadian Securities Administrators at www.sedar.com. Investors and security holders may obtain free copies of the documents filed by POZEN with the SEC on POZEN's website at www.pozen.com under the heading "Investors" and then under the heading "SEC Filings" and free copies of the documents filed by Tribute with the SEC on Tribute's website at www.tributepharma.com under the heading "Investors" and then under the heading "SEC Filings."

POZEN, Tribute and Aralez and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of POZEN and shareholders of Tribute and Aralez in connection with the proposed transaction. Information regarding the special interests, if any, of these directors and executive officers in the proposed transaction will be included in the proxy statement/prospectus and Information Circular described above. Additional information regarding the directors and executive officers of POZEN and Tribute is contained in their respective annual reports on Form 10-K for the year ended December 31, 2014 filed with the SEC.

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

For full prescribing information refer to the individual product websites.

About Tribute

Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution 2%), Fiorinal®, Fiorinal® C, Visken®, Viskazide®, Collatamp® G, Durela®, Proferrin®, Iberogast®, MoviPrep®, Normacol®, Resultz®, Pegalax®, Balanse®, Balanse® Kids, Diaflor™, Mutaflor®, and Purfem® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to Fibricor® and its related authorized generic. In addition, it has the exclusive U.S. rights to develop and commercialize Bezalip® SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. This product is subject to receiving Canadian regulatory approval. Tribute also has the Canadian rights to ibSium®, which was approved in Canada in June 2015 and two additional pipeline products including Octasa® and BedBugz™, both of which are pending submission to Health Canada.

Tribute's common shares are traded on the TSX Venture Exchange under the symbol "TRX" and on the OTCQX International under the symbol "TBUFF". For more detailed company information, including copies of this and other press releases, please visit www.tributepharma.com.

About POZEN

POZEN is a specialty pharmaceutical company that has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained United States Food and Drug Administration ("FDA") approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

On June 2, 2015, POZEN announced the formation of Aralez Pharmaceuticals Trading DAC (formerly "Pozen Limited"), a wholly-owned Irish subsidiary, to expand its geographic footprint and increase its global presence, including potential international sales, manufacturing and product development.

POZEN's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

http://www.marketwired.com/press-release/tribute-schedules-special-shareholder-meeting-for-february-1-2016-tsx-venture-trx-2084618.htm

QLT Calls Special Meeting of Its Shareholders in Connection With Aralez Pharmaceuticals Transaction (12/28/15)

Provides Update on Return of Capital

VANCOUVER, British Columbia, Dec. 28, 2015 (GLOBE NEWSWIRE) -- QLT Inc. (NASDAQ:QLTI) (TSX:QLT) (“QLT”) today announced that it has called a special meeting of its shareholders (the “Special Meeting”) to approve a reorganization of its share capital pursuant to a statutory plan of arrangement (the “Share Reorganization”). As discussed below, if approved, the Share Reorganization is expected to permit QLT to distribute common shares of Aralez Pharmaceuticals Inc. (“Aralez”) to QLT shareholders in a tax efficient manner. It is anticipated that the Special Meeting will be held on February 11, 2016, in Vancouver, Canada.

Further to QLT’s press releases issued on June 8, 2015 and December 7, 2015, QLT has agreed to make an equity investment of US$45 million in Aralez, which will be a newly formed company resulting from the pending merger transaction between POZEN Inc. (NASDAQ:POZN) (“POZEN”) and Tribute Pharmaceuticals Canada Inc. (TSX-V:TRX) (OTCQX:TBUFF) (“Tribute”). The POZEN - Tribute merger transaction and QLT’s equity financing in Aralez are expected to close in the first quarter of 2016. Upon closing, Aralez common shares are expected to trade on the NASDAQ and TSX.

As part of the Share Reorganization, following its acquisition of Aralez common shares QLT intends to distribute such shares to its shareholders. In connection with that distribution, QLT has made arrangements with third parties so that QLT shareholders will be given the opportunity to elect to receive, in lieu of Aralez shares, up to an aggregate of $15 million in cash, subject to pro ration among the shareholders. Details of the distribution of the Aralez common shares under the Share Reorganization and certain anticipated tax consequences of such distribution will be contained in the Proxy Statement to be prepared by QLT and mailed to its shareholders in connection with the Special Meeting.

QLT also confirms that the board of directors of QLT has further considered and determined that in light of the termination of the merger with InSite Vision Incorporated (“InSite”) and other factors, it is not in the best interests of QLT at this time to issue to QLT’s shareholders up to $25 million of redeemable convertible notes. The issuance of the notes had been previously contemplated and announced by QLT on June 8, 2015 in connection with its proposed merger with InSite and had been subject to certain conditions, including a formal approval of the notes by the board.

About QLT

QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases.

QLT’s head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ Stock Market (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company’s products and developments, please visit our web site at www.qltinc.com.

Important Information For Investors And Shareholders

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the transactions referred to in this material, QLT expects to file a proxy statement with the Securities and Exchange Commission (“SEC”). This material is not a substitute for the proxy statement or for any other document that QLT may file with the SEC and send to QLT’s shareholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF QLT ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the proxy statement (when available) and other documents filed with the SEC by QLT through the website maintained by the SEC at http://www.sec.gov and also on the System for Electronic Document Analysis Retrieval (“SEDAR”) website maintained by the Canadian Securities Administrators at www.sedar.com. QLT stockholders may also obtain these documents, free of charge, from QLT's website at www.qltinc.com under the heading "Investors" and then under the heading "Proxy Circulars" or upon request directly to QLT to the attention of "QLT Investor Relations," 887 Great Northern Way, Suite 250, Vancouver, British Columbia, Canada, V5T 4T5.

QLT and certain of its directors and executive officers may be considered participants in the solicitation of proxies with respect to the proposed transaction under the rules of the SEC. Information about the directors and executive officers of QLT is set forth in its Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 26, 2015. This document can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in any proxy statement and other relevant materials to be filed with the SEC when they become available.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute “forward-looking information” within the meaning of applicable Canadian securities laws. Forward looking statements include, but are not limited to, statements concerning the proposed closing of the combination of Tribute and POZEN under Aralez, the proposed investment in Aralez and the subsequent distribution of the Aralez shares (or cash in lieu) to QLT shareholders, the intention of certain third parties to provide a $15 million backstop for those QLT shareholders who elect to receive cash in lieu of Aralez shares (subject to proration) and the availability of certain liquidity events for shareholders (collectively, the “Proposed Transactions”) including any statements regarding the expected timetable for completing the Proposed Transactions, including the timing for holding the Special Meeting, the effect of the Proposed Transactions on QLT and the QLT shares, the future potential of Aralez and any other statements regarding QLT’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are “forward-looking” statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are often, but not always, made through the use of words or phrases such as “believe,” “expect,” “anticipate,” “should,” “planned,” “will,” “may,” “intend,” “estimated,” “aim,” “on track,” “target,” “opportunity,” “tentative,” “positioning,” “designed,” “create,” “predict,” “project,” “seek,” “would,” “could,” “potential,” “continue,” “ongoing,” “upside,” “increases,” and “potential” and similar expressions. All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the statements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking statements are the following: the timing to consummate the Proposed Transactions; the risk that a condition to closing the Proposed Transactions may not be satisfied; the risk that POZEN or Aralez stock price could decline; and uncertainties relating to QLT’s development plans, timing and results of the clinical development and commercialization of QLT’s products and technologies. Additional information concerning these and other factors can be found in QLT’s filings with the SEC, including QLT’s most recent Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. QLT assumes no obligation to update any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking that speak only as of the date hereof.
QLT Inc. Contacts:

For Investors:

Andrea Rabney or David Pitts
Argot Partners
P: 212-600-1902
andrea@argotpartners.com
david@argotpartners.com

For Media:

Chuck Burgess or Mike Pascale
Abernathy MacGregor
P:212-371-5999
clb@abmac.com
mmp@abmac.com

http://globenewswire.com/news-release/2015/12/28/798213/0/en/QLT-Calls-Special-Meeting-of-Its-Shareholders-in-Connection-With-Aralez-Pharmaceuticals-Transaction.html

Pozen, Inc and Tribute Pharmaceuticals merger to create Aralez Pharmaceuticals.

Pozen shareholders will receive one share of Aralez for each share of Pozen they own, while Tribute shareholders will receive one Aralez share for every 6.88 shares they own, so investors can gain access to Aralez by investing in shares of either of those companies. Once the merger closes, the new Aralez will trade on the NASDAQ under ARLZ and in Canada on the TSX under ARZ.

SWK Holdings Announces Portfolio Changes (12/22/15)

PDI, Inc.

On October 31, 2014, SWK Funding LLC, a Delaware limited liability company (the “Company”) and wholly-owned subsidiary of SWK Holdings Corporation, a Delaware corporation (“SWK Holdings”), entered into a credit agreement pursuant to which the Company provided to PDI, Inc. (the “PDI”) a term loan in the principal amount of $20,000,000.

On December 22, 2015, PDI repaid all of its outstanding obligations to the Company for an aggregate amount of $21,881,365, which included an exit fee of $1,600,000 and $270,000 of accrued interest.

Cambia Royalty

On July 31, 2014, the Company purchased 25% of a royalty stream paid on the net sales of Cambia®, an NSAID pharmaceutical product indicated for the treatment of migraine. Cambia® is marketed in the United States by Depomed, Inc. and in Canada by Tribute Pharmaceuticals Canada Inc.

On December 9, 2015, the Company purchased an additional 25% of the royalty stream for an initial purchase price of $4,500,000. The purchase was structured in the same manner as the initial purchase and provides for additional contingent consideration of (i) $500,000 to be paid by the Company to the seller upon Cambia® reaching certain net sales and (ii) annual sharing payments to be remitted to the seller once aggregate royalty payments received by the Company exceed certain thresholds.

http://www.sec.gov/Archives/edgar/data/1089907/000155278115001113/e00462_swk-8k.htm

Best Long Idea For 2016 50% Undervalued (12/07/15)

http://seekingalpha.com/research/957061-chris-demuth-jr/4609746-best-long-idea-for-2016-50-percent-undervalued

30% Upside To StW's Top Stock For 2016 (12/01/15)

http://seekingalpha.com/article/3724226-30-percent-upside-to-stws-top-stock-for-2016

TBUFFY and the price slayer.

Amended 8-K/A Issued After Close Today:

Click on Blue Highlighted section at the link below

Enjoy dp

http://ir.stockpr.com/tributepharma/all-sec-filings#document-21599-0001354488-15-003575

$TBUFF recent news/filings

bullish
bull flag breakout
higher highs, higher lows uptrend
recent bullish engulfing candlestick
climbing acc/dist line

## source: finance.yahoo.com

Mon, 22 Jun 2015 21:02:12 GMT ~ TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acq


read full: http://biz.yahoo.com/e/150622/tbuff8-k.html
*********************************************************

Wed, 17 Jun 2015 12:41:06 GMT ~ Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company

[at noodls] - Includes Canadian Rights to Durela(R), Proferrin(R) and 13 Additional Products MILTON, ONTARIO -- (Marketwired) -- 06/17/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ('Tribute' ...

read full: http://www.noodls.com/view/3DAE3BE287CE4835B80DC1F30C7A48BA171DC925
*********************************************************

Wed, 17 Jun 2015 12:29:00 GMT ~ Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company

[Marketwired] - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is ...

read full: http://finance.yahoo.com/news/tribute-pharmaceuticals-announces-acquisition-medical-122900822.html
*********************************************************

Fri, 12 Jun 2015 19:04:19 GMT ~ TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Stateme


read full: http://biz.yahoo.com/e/150612/tbuff8-k.html
*********************************************************

Wed, 10 Jun 2015 15:45:00 GMT ~ TBUFF: POZEN will acquire Tribute Pharma and become Aralez Pharma PLC.


read full: http://finance.yahoo.com/news/tbuff-pozen-acquire-tribute-pharma-154500152.html
*********************************************************

$TBUFF charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$TBUFF company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/TBUFF/company-info
Ticker: $TBUFF
OTC Market Place: OTCQX International
CIK code: 0001159019
Company name: Tribute Pharmaceuticals Canada Inc.
Company website: http://www.tributepharma.com
Incorporated In: Canada

Business Description: Tribute Pharmaceuticals Canada Inc. is an emerging Canadian specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S.


$TBUFF share structure

## source: otcmarkets.com

Market Value: $151,247,013 a/o Jul 17, 2015
Shares Outstanding: 94,476,240 a/o Jul 15, 2014
Float: 14,893,018 a/o Jul 14, 2014
Authorized Shares: Unlimited a/o Jul 14, 2014
Par Value: No Par Value

$TBUFF extra dd links

Company name: Tribute Pharmaceuticals Canada Inc.
Company website: http://www.tributepharma.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=TBUFF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=TBUFF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=TBUFF+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/news - http://finance.yahoo.com/q/h?s=TBUFF+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/TBUFF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=TBUFF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/TBUFF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Tribute+Pharmaceuticals+Canada+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Tribute+Pharmaceuticals+Canada+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Tribute+Pharmaceuticals+Canada+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.tributepharma.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.tributepharma.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.tributepharma.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/TBUFF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001159019&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=TBUFF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=TBUFF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=TBUFF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=TBUFF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=TBUFF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=TBUFF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=TBUFF+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/TBUFF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=TBUFF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/TBUFF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=TBUFF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/TBUFF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/TBUFF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/TBUFF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=TBUFF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=TBUFF



$TBUFF DD Notes ~ http://www.ddnotesmaker.com/TBUFF

TBUFF BOOM!!

$TBUFF Chart - what an incredible run since the start of the New Year - currently on a 9 day run & getting extremely Frothy - Fast Sto & RSI are running out juice / room to run - Fast Sto is maxed @ 100.00 - keep an EYE on the 2 ascending support lines - they should provide support on a pullback -

Hope you aren't just watching but buying as well. I think the ride here has just begun. Check out the stockhouse board for Tribute Pharmaceuticals and the Yahoo board for Pozen. Good discussions on both regarding what is transpiring here. I think there will be many more acquisitions prior to the Tribute and Pozen deal closing 4th quarter. If you get a chance, read kuatolives' posts on the stockhouse board. Good luck!

TBUFF on watch

Tribute Acquires Medical Futures Inc. Expanding portfolio

This acquisition further diversifies Tribute's product portfolio in Canada through the addition of 13 marketed and 2 pipeline products. Highlights of the MFI portfolio include Durela®, Proferrin® and Resultz®.

See link below for further details.

Enjoy dp

http://finance.yahoo.com/news/tribute-pharmaceuticals-announces-acquisition-medical-122900822.html

Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Includes Canadian Rights to Durela(R), Proferrin(R) and 13 Additional Products
Marketwired Tribute Pharmaceuticals Canada Inc.


MILTON, ONTARIO--(Marketwired - Jun 17, 2015) - Tribute Pharmaceuticals Canada Inc. (TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that it has acquired Medical Futures Inc. ("MFI") in a transaction valued at $25 million. Financial terms of the deal include the payment of: $8.3 million in cash on closing; $5 million through the issuance of 3,723,008 common shares in the capital of Tribute; and, $5 million in the form of a one year term promissory note bearing interest at 8% annually convertible at MFI's option at any time during the term into 2,813,778 common shares of Tribute; and future contingent cash milestone payments totaling $6 million based on attainment of certain conditions expected shortly after the close of this transaction. Net Sales of MFI in the twelve month period ended March 31, 2015 were approximately $10 million. This transaction is expected to be immediately accretive. Unless otherwise indicated herein, all references to monetary amounts are in Canadian dollars.

Interesting read from poster named "kuatolives" on the Tribute board at stockhouse.com.

POZN/Aralez could merge again before Q4
From the US Treasury Department:

"An inverted company is subject to potential adverse tax consequences if, after the transaction: (1) less than 25 percent of the new multinational entity’s business activity is in the home country of the new foreign parent, and (2) the shareholders of the old U.S. parent end up owning at least 60 percent of the shares of the new foreign parent. If these criteria are met for an inverted company, the tax consequences depend on the continuing ownership stake of the shareholders from the former U.S. parent. If the continuing ownership stake is 80 percent or more, the new foreign parent is treated as a U.S. corporation (despite the new corporate address), thereby nullifying the inversion for tax purposes. If the continuing ownership stake is at least 60 but less than 80 percent, U.S. tax law respects the foreign status of the new foreign parent but other potentially adverse tax consequences may follow. The current wave of inversions involves transactions in this continuing ownership range of 60 to 80 percent."

Given the new US treasury rules intended to throttle inversions, it's possible the nature of the TRX/POZN deal included the equity stake to Deerfield (resulting in an equity split of 28% to TRX, 54% to POZN and 17% to Deerfield) to keep parent sharehoulder equity under 60%. Going forward, this would put Aralez into a position to merge with yet another company of roughly 1.25B in valuation so the larger parent could 'buy into' the tax inversion and still maintain sub 60% ownership (sans any more equity buy-ins). It's not inconceivable this relatively low embarkation point could lead to a cascade of mergers with Aralez as other companies continually buy-into the Irish domicile, each deal of higher and higher valuations, but each company staying under a 60% equity stake. TRX shares today could be worth a helluva lot of money in a few years. It's also possible we could see the first such deal before Yosprala is approved by the FDA, as the value of POZN would theoretically be more after approval, therefore more expensive to buy-in. It's interesting that the new US treasury rules intended to thrwart inversions might actually create a cascade of them. glta.

Read more at http://www.stockhouse.com/companies/bullboard/tbuff/tribute-pharmaceuticals-canada-inc#YQdeuVThCOzhZpi2.99

PR from QLT Inc regarding investment in Aralez

More details of the POZN - TBUFF acquisition / merger and Aralez creation at the link below.

Also Zacks analysis at 2nd link below that.

Enjoy dp

http://www.qltinc.com/newsCenter/documents/PressReleaseQLTAnnouncesMultipleTransactionsDesignedtoTransformtheCompany.pdf

TBUFF: POZEN will acquire Tribute Pharma and become Aralez Pharma PLC.

http://finance.yahoo.com/news/tbuff-pozen-acquire-tribute-pharma-154500152.html

(POZN) Tribute to Unite Under Newly Formed Aralez Label

The main thing I don't understand is How? can they estimate the value of the new combined company (Aralez Pharmaceuticals plc) along with Tribute and Pozen's share price value if Aralez has no share price value? Isn't the value of the new company what the market purchases of it's shares say it is?

Anyone? With a clue how they are pre-determining the $$$ value of the deal??

Also read elsewhere today: QLT also said it has agreed to make a $45 million equity investment in Aralez Pharmaceuticals plc. So isn't the share price value of Alarez still a fluid, moveable amount?


TIA & Enjoy dp


https://www.biospace.com/News/pozen-inc-tribute-to-unite-under-newly-formed/380423

June 8, 2015
By Alex Keown, BioSpace.com Breaking News Staff

NEW YORK – North Carolina-based Pozen, Inc. (POZN) will acquire Tribute Pharmaceuticals Canada for $146 million. Both companies will unite under the newly formed named Aralez Pharmaceuticals, which will be based in Ireland.

The new company will utilize the products and pipelines from both pharmaceutical companies. The Aralez deal resulting in the combination of Pozen and Tribute is subject to stockholder approval by the Pozen and Tribute stockholders as well as other closing conditions. Aralez Pharmaceuticals Ltd. will re-register as Aralez Pharmaceuticals plc upon closing of such transactions. If all goes well, the deal is expected to be finalized by the end of 2015.

Adrian Adams, Pozen’s chief executive officer, said the acquisition will “enhance our offerings while providing significant benefits for all of our stakeholders.”

Rob Harris, CEO of Tribute, said the deal will allow the company to “leverage the expertise of its management team across the healthcare, pharmaceutical and, in particular, cardiovascular sectors.”

In response to the news, Pozen Inc.’s stock was trading at $9.09 per share this morning, up from the opening price of $8.50 per share. Tribute Pharmaceutical’s stock was also trending upward, trading at $1.23 per share, up from the opening of $1.05 per share.

The new Aralez has already received $300 million in funding provided by Deerfield Management Company. Under terms of the agreement Deerfield will provide $75 million in six year convertible notes, up to $25 million in equity and a $200 million commitment available for future product acquisitions. The new company will bring together the management team of both Tribute and Pozen, Deerfield said. However, there was no word on whether or not the new company would issue pink slips to avoid redundant positions, or would require additional employees to bolster new pipeline avenues. Deerfield did not respond to BioSpace (DHX) inquiries by the time this article was published.

Aralez will use the capital funding to launch Yosprala upon approval from the U.S. Food and Drug Administration (FDA). Yosprala is Pozen’s “safer aspirin" product that contains either 325 mg or 81 mg of enteric-coated aspirin surrounded by 40 mg of immediate release omeprazole. In December Pozen and Sanofi (SNY) terminated their agreement to commercialize Yosprala in the United States. The two companies stuck an agreement in 2013 that included $15 million in upfront money, an additional $20 million in milestone payments and tiered royalties of 12.25 to 22.5 percent. Also in December Pozen received two complete response letters from the FDA after investigators found deficiencies during an inspection of a foreign manufacturing facility. There were no clinical or safety issues noted in the letters with respect to the drugs, and no other problems were cited.

With this vote of confidence, Aralez will have a unique mix of capital, products and talent, enabling us to drive significant innovation and growth,” Adams said in a statement.

In addition to Yosprala, Pozen also makes Treximet, an FDA approved drug for migraines. The company also co-developed Vimovo with AstraZeneca PLC (AZN). Vimovo was approved by the FDA for the relief of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

Tribute markets migraine medication Cambia, hyperlipidaemia drug Bezalip SR, psoriasis drug Soriatane, NeoVisc, for the treatment of joint pain and others.

$TBUFF recent news/filings

bullish

## source: finance.yahoo.com

Mon, 08 Jun 2015 14:59:00 GMT ~ IIROC Trading Resumption - TRX

[CNW Group] - IIROC Trading Resumption - TRX

read full: http://finance.yahoo.com/news/iiroc-trading-resumption-trx-145900498.html
*********************************************************

Mon, 08 Jun 2015 14:46:22 GMT ~ POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors

[Marketwired] - POZEN Inc. , a pharmaceutical company committed to developing medicine that transforms lives, today announced the acquisition of Tribute Pharmaceuticals Canada Inc. , a Canadian specialty pharmaceutical ...

read full: http://finance.yahoo.com/news/pozen-announces-strategic-acquisition-tribute-144622322.html
*********************************************************

Mon, 08 Jun 2015 14:45:00 GMT ~ POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors

[Business Wire] - POZEN Inc. , a pharmaceutical company committed to developing medicine that transforms lives, today announced the acquisition of Tribute Pharmaceuticals Canada Inc.

read full: http://finance.yahoo.com/news/pozen-announces-strategic-acquisition-tribute-144500688.html
*********************************************************

Thu, 28 May 2015 21:30:47 GMT ~ TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acq


read full: http://biz.yahoo.com/e/150528/tbuff8-k.html
*********************************************************

Thu, 21 May 2015 20:43:19 GMT ~ Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor®, Commercial Expansion into U.S. Market and Completion of $12 Million Equity Financing

[at noodls] - - William Maichle Hired as President of U.S. Operations MILTON, ONTARIO--(Marketwired - May 21, 2015) - NOT FOR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Tribute Pharmaceuticals ...

read full: http://www.noodls.com/view/FC85EB0573D11D4F7BDD1E3849103DF16E8FECCD
*********************************************************

$TBUFF charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$TBUFF company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/TBUFF/company-info
Ticker: $TBUFF
OTC Market Place: OTCQX International
CIK code: 0001159019
Company name: Tribute Pharmaceuticals Canada Inc.
Company website: http://www.tributepharma.com
Incorporated In: Canada

Business Description: Tribute Pharmaceuticals Canada Inc. is an emerging Canadian specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S.


$TBUFF share structure

## source: otcmarkets.com

Market Value: $99,200,052 a/o Jun 05, 2015
Shares Outstanding: 94,476,240 a/o Jul 15, 2014
Float: 14,893,018 a/o Jul 14, 2014
Authorized Shares: Unlimited a/o Jul 14, 2014
Par Value: No Par Value

$TBUFF extra dd links

Company name: Tribute Pharmaceuticals Canada Inc.
Company website: http://www.tributepharma.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=TBUFF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=TBUFF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=TBUFF+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/news - http://finance.yahoo.com/q/h?s=TBUFF+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/TBUFF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=TBUFF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/TBUFF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Tribute+Pharmaceuticals+Canada+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Tribute+Pharmaceuticals+Canada+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Tribute+Pharmaceuticals+Canada+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.tributepharma.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.tributepharma.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.tributepharma.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/TBUFF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001159019&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=TBUFF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=TBUFF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=TBUFF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=TBUFF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=TBUFF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=TBUFF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=TBUFF+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/TBUFF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=TBUFF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/TBUFF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=TBUFF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/TBUFF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/TBUFF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/TBUFF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=TBUFF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=TBUFF



$TBUFF DD Notes ~ http://www.ddnotesmaker.com/TBUFF

POZEN Announces Strategic Acquisition of Tribute

Seems to value shares at $1.28 USD at this point or about a 20% premium to Friday's close of $1.05.

Trading up after trade halt resumption to $1.25 on 123,000 shares after 10 minutes at 11:25 EST but pulling back to $1.15 soon after.

POZN up around 20% to around $9. See link for details.

Enjoy dp

http://finance.yahoo.com/news/pozen-announces-strategic-acquisition-tribute-144500688.html

200K Block pretty much at the ask

$0.986 (ask $0.99) a few minutes before the close. Most daily volume traded in over 4 years. Lookin Good!

Enjoy dp

Last Price Today’s Change Bid (Size) Ask (Size) Day’s Range Volume
0.986 +0.077 (+8.47%) 0.913 x1,000 1.03 x100 0.95 - 1.06 848,030

Link to Daily and Weekly Charts:

http://stockcharts.com/h-sc/ui?s=TBUFF&p=D&b=5&g=0&id=p81540834300

Broke into Dollarland on increasing volume

Been a good, steady rise since closing last year at $0.46. Looking strong and mostly undiscovered.

Enjoy dp

http://stockcharts.com/h-sc/ui?s=TBUFF&p=W&b=5&g=0&id=p43454271255

Link below to 1st quarter CC transcript
http://seekingalpha.com/article/3174826-tribute-pharmaceuticals-canadas-tbuff-ceo-robert-harris-on-q1-2015-results-earnings-call-transcript

The audio is on their website in the IR section.

Great quarter - could be a fun few years with this one!

It is still very quiet around here - which to me means this one hasn't even started to run yet. Perhaps uplisting to the TSX later this year will draw a few more eyes.

Looks good. I have been buying over the last several months. I think this one is undervalued.

Here is a link to the company's website where they have uploaded a copy of the slides from the presentation at the healthcare investor conference they presented at today - some interesting tidbits included:
http://ir.stockpr.com/tributepharma/presentations

The company has released nothing new since the March year end conference call. Here is a link to the transcript from the CC which is very informative overall. I think on page 5 there is a brief discussion on Bezalip. Hopefully we'll get an update in May with Q1 earnings release and CC.

http://seekingalpha.com/article/2969656-tribute-pharmaceuticals-canadas-tbuff-ceo-rob-harris-on-q4-2014-results-earnings-call-transcript

Does anyone have a ideal when Bezalip will get final approval from the FDA.

Tribute Pharmaceuticals Added to the S&P/TSX Venture Composite Index

$TBUFF recent news/filings

bullish

## source: finance.yahoo.com

Thu, 02 Apr 2015 13:27:15 GMT ~ Tribute Pharmaceuticals to Participate at Laurentian Bank Securities Annual Investor Conference

[at noodls] - MILTON, ONTARIO -- (Marketwired) -- 04/02/15 -- Tribute Pharmaceuticals Canada Inc. ("Tribute" or the "Company") (TSX VENTURE:TRX) (OTCQX:TBUFF), a specialty pharmaceutical company ...

read full: http://www.noodls.com/view/C8AE268A677BB7380A93821D6799BF66365CE25B
*********************************************************

Thu, 02 Apr 2015 13:15:00 GMT ~ Tribute Pharmaceuticals to Participate at Laurentian Bank Securities Annual Investor Conference

[Marketwired] - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today ...

read full: http://finance.yahoo.com/news/tribute-pharmaceuticals-participate-laurentian-bank-131500727.html
*********************************************************

Thu, 19 Mar 2015 23:18:31 GMT ~ Tribute Raises US$2.7 Million Through the Exercise of Warrants

[at noodls] - MILTON, ONTARIO -- (Marketwired) -- 03/19/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with ...

read full: http://www.noodls.com/view/EE58B2E61D6820362F6AD9675D47A5B949FC8D4D
*********************************************************

Thu, 19 Mar 2015 23:18:31 GMT ~ Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results

[at noodls] - 4th Quarter Revenue Up 70.5% and EBITDA Up 217% Over Comparative Periods MILTON, ONTARIO -- (Marketwired) -- 03/03/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" ...

read full: http://www.noodls.com/view/A2AD7AD520DB31995F6AC0BDB7C2983589FB14A2
*********************************************************

Thu, 19 Mar 2015 22:47:46 GMT ~ Tribute Raises US$2.7 Million Through the Exercise of Warrants

[Marketwired] - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, ...

read full: http://finance.yahoo.com/news/tribute-raises-us-2-7-224746887.html
*********************************************************

$TBUFF charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$TBUFF company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/TBUFF/company-info
Ticker: $TBUFF
OTC Market Place: OTCQX International
CIK code: 0001159019
Company name: Tribute Pharmaceuticals Canada Inc.
Company website: http://www.tributepharma.com
Incorporated In: Canada

Business Description: Tribute Pharmaceuticals Canada Inc. is an emerging Canadian specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S.


$TBUFF share structure

## source: otcmarkets.com

Market Value: $68,022,893 a/o Apr 07, 2015
Shares Outstanding: 94,476,240 a/o Jul 15, 2014
Float: 14,893,018 a/o Jul 14, 2014
Authorized Shares: Unlimited a/o Jul 14, 2014
Par Value: No Par Value

$TBUFF extra dd links

Company name: Tribute Pharmaceuticals Canada Inc.
Company website: http://www.tributepharma.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=TBUFF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=TBUFF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=TBUFF+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/news - http://finance.yahoo.com/q/h?s=TBUFF+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/TBUFF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=TBUFF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/TBUFF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Tribute+Pharmaceuticals+Canada+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Tribute+Pharmaceuticals+Canada+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Tribute+Pharmaceuticals+Canada+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.tributepharma.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.tributepharma.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.tributepharma.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/TBUFF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001159019&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=TBUFF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=TBUFF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=TBUFF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=TBUFF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=TBUFF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=TBUFF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=TBUFF+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/TBUFF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=TBUFF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/TBUFF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=TBUFF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/TBUFF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/TBUFF/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/TBUFF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/TBUFF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/TBUFF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=TBUFF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=TBUFF



$TBUFF DD Notes ~ http://www.ddnotesmaker.com/TBUFF

Nice move lately. Holding a good position

Re-listened to their 3rd quarter CC on Tribute's website. They expected the drugs in the Novartis deal to be immediately accretive, but were not going to be doing promotion via their sales reps until Q1 2015 on these drugs as I guess they are all getting up to speed. I suspect we will see a bigger bump in Q1 from the Novartis deal. They certainly look like they are on track to see a top line growth of 50% in 2015.

As I've had time to analyze today's PR a little more, it seems to me expected 4rth quarter revenue of $5.2M is a little bit of a let down. 3rd quarter revenue was $3.8M. The 10/2 transaction which added licenses for drugs that had a 12 month trailing revenue (see company presentation on their website) of $10M should have added at least $2.5M to the company's 4rth quarter revenue. Am I missing something here or is this revenue number a disappointment? TIA

nice update from the company today

http://finance.yahoo.com/news/tribute-pharmaceuticals-provides-2014-revenues-133000212.html

Anyone paying any attention to this stock? Bought in last fall. Looks like they are finally starting to pick up traction. Volume has exploded the past few days on the Toronto exchange for TRX (symbol for Tribute there). Per 3rd quarter conference call, they were expecting a good 4rth quarter - possibly positive EBITA. We could see a nice steady climb leading up to earnings release in March.

Fidelity now owns 10%.

Hello

Knock Knock, Anyone Home?

Break-out!...0,80$ without news.
Chart simply spectacular: http://stockcharts.com/h-sc/ui?s=tbuff

Another coverage out...1,00 $Usd rating.

http://finance.yahoo.com/news/tbuff-pharmaceutical-company-strong-upside-150000193.html

Nice coverage out, with 1,85 Cad$ 12 months target.
...sweet!

http://finance.yahoo.com/news/mackie-research-updates-coverage-tribute-152402592.html

chart looking for a solid floor around 50 ema.
Hold & load 0,50/55 support is crucial to reach one buck for this summer.
http://stockcharts.com/h-sc/ui?s=tbuff

More Good

Gross Profit and Cost of Sales

Gross profit for the three month period ended March 31, 2014 was $1,734,600, higher by 3.5%, or $58,700 compared to the same period in the prior year. Underlying improvements in gross profit for the three month period ended March 31, 2014 were due to additional gross profit of $258,200 from licensed domestic product net sales. Serving as a partial offset was a decrease in gross profit from other domestic product sales and international product sales of $119,800 and from royalty and licensing revenue of $79,600. Excluding gross profit associated with the Cambia ® initial buy-in in the first quarter of 2013, the adjusted gross profit in that period was $1,174,200. This represents an increase in the gross profit of $560,500 or 47.7% for first quarter of 2014 compared to the same period in the prior year.

10Q looks good to me so far..

On May 13, 2014, Tribute entered into an exclusive license and supply agreement with Faes Farma, S.A. (“Faes”), a Spanish pharmaceutical company, for the exclusive right to sell Bilastine, a product for the treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria (hives) in Canada. The exclusive license is inclusive of prescription and non-prescription rights for Bilastine, as well as adult and paediatric presentations in Canada. Sales of Bilastine are subject to receiving regulatory approval from Health Canada. Payment for the licensing rights is based on an initial fee of €250,000 ($380,691) with the remaining milestone payments based on the achievement of specific events, including the approval of Bilastine from Health Canada and net sales milestones.